Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth

Evotec SE, a German drug discovery powerhouse, continues to expand its US footprint amid biotech sector volatility, offering contract research services to major pharma players.

Evotec SE maintains its position as a key player in the global drug discovery and development services market. The company reported steady progress in its partnerships with leading pharmaceutical firms in its fiscal year 2025 results, published on March 27, 2026, according to Evotec IR as of 03/27/2026. Shares traded at approximately 8.50 EUR on Xetra on May 13, 2026, reflecting resilience in a challenging biotech environment.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec SE
• Sector/industry: Biotechnology / Drug Discovery Services
• Headquarters/country: Hamburg, Germany
• Core markets: US, Europe
• Key revenue drivers: Integrated drug discovery, development partnerships
• Home exchange/listing venue: Xetra (EVT.DE)
• Trading currency: EUR

Evotec SE: core business model

Evotec SE operates an asset-agnostic drug discovery and development platform, partnering with big pharma and biotech companies to advance novel therapies. The company integrates industrial processes with cutting-edge technologies like AI-driven target identification and high-throughput screening. In 2025, Evotec's EVT Execute division generated 68% of group revenues from full-service partnerships, per its annual report published March 27, 2026, according to Evotec annual report as of 03/27/2026.

This model allows Evotec to share risks and rewards through milestone payments and royalties, reducing reliance on upfront fees. Headquartered in Hamburg, the firm employs over 5,000 scientists across sites in Europe and the US, with key facilities in Princeton, New Jersey, enhancing its appeal to US investors tracking biotech outsourcing trends.

Main revenue and product drivers for Evotec SE

Evotec's revenues stem primarily from its three business units: EVT Execute (contract research), EVT Innovate (proprietary programs), and platform investments. For fiscal 2025 (ended Dec 31, 2025), total revenues reached €751 million, up 4% year-over-year, driven by Execute segment growth, as detailed in the annual report published March 27, 2026, according to Evotec IR as of 03/27/2026. Key drivers include long-term alliances with firms like Bristol Myers Squibb and Janssen.

The company's pipeline features over 20 clinical-stage programs, many co-developed with partners. Notable assets include a JAK1 inhibitor for vitiligo in Phase II and metabolic disease candidates, providing potential royalty streams for US investors interested in biotech innovation.

Industry trends and competitive position

The drug discovery outsourcing market is projected to grow at 7.5% CAGR through 2030, fueled by big pharma's need to fill pipelines amid patent cliffs, per IQVIA data published January 2026, according to IQVIA as of 01/2026. Evotec competes with firms like Charles River Laboratories and WuXi AppTec but differentiates via its end-to-end platform and AI integration.

Evotec's US exposure, with 40% of revenues from North America in 2025, positions it well for American investors. Its Princeton campus supports CNS and oncology programs, aligning with high US R&D spending in these areas.

Why Evotec SE matters for US investors

Evotec's OTC listing (EVTKY) provides US investors direct access to European biotech services without ADR complexities. Partnerships with US giants like Eli Lilly underscore its role in the $50 billion US pharma outsourcing market. The stock's liquidity on Nasdaq OTC appeals to retail portfolios seeking biotech diversification.

With the US biotech index up 15% YTD as of May 2026, Evotec offers exposure to sector tailwinds like AI in drug discovery, relevant for US funds tracking global CROs.

Conclusion

Evotec SE demonstrates operational resilience with diversified revenues and a robust partnership network. While biotech markets remain volatile, the company's US-centric growth and tech-enabled platform provide a compelling profile for monitoring. Investors should track upcoming milestones and Q1 2026 results for further insights into performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.